PUBLIC PRIVATE PARTNERSHIP FOR BIOMEDICAL RESEARCH UNDER HORIZON 2020: PATIENTS’ PERSPECTIVE ON SCIENTIFIC PRIORITIES

Track:
Stand-Alone Sessions

Day & Time:
March 5, 9:00AM - 10:30AM

Session Number:
1801

Room Number:
G107

Type:
Session

Title:
PUBLIC PRIVATE PARTNERSHIP FOR BIOMEDICAL RESEARCH UNDER HORIZON 2020: PATIENTS’ PERSPECTIVE ON SCIENTIFIC PRIORITIES

Chair(s):
Anders Ekblom
Executive Vice President R&D and Technology Integration
AstraZeneca, Sweden

Description:
The Innovative Medicines Initiative (IMI) set up under Framework Programme 7 has demonstrated its value in advancing biomedical research in a public private partnership set up. IMI sets a model for large scale open collaborations between industry and public partners (academia, SMEs, patient groups, authorities/regulators) and delivers results at a much better pace than any other existing research funding scheme. Building on the successes and achievements of the Innovative Medicines Initiative, EFPIA is envisaging renewing this public private partnership experience under Horizon 2020. Patient organisations will be invited to provide their views and in particular on the following questions: • What are main treatment gaps/unmet medical needs (lack of treatment, poor response to existing treatment, side effects, dosage/form, etc.)? • What are the barriers for delivery of adequate treatments (lack of screening or diagnostic, reimbursement, etc.)? • What are other challenges not addressed in previous questions (patient care, adapted infrastructure, stigmatisation, information, etc.)?

Presentation(s) & Speaker(s):
Health Research Objectives in Horizon 2020
Jeremy Bray
Policy Officer
European Commission, DG Research & Innovation, Belgium

Key Objectives of the Future PPP – combining research, health and regulatory agendas: right prevention and treatment, for the right patient, at the right time
Anders Ekblom
Executive Vice President R&D and Technology Integration
AstraZeneca, Sweden